United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $568.81, for a total transaction of $5,403,695.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $23,044,199.53. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $569.11 on Wednesday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $607.89. The company has a market capitalization of $24.94 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 1.61 and a beta of 0.75. The firm’s 50-day moving average is $540.11 and its two-hundred day moving average is $496.38.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. During the same quarter in the prior year, the firm earned $6.19 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Raymond James Financial began coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Morgan Stanley upped their price target on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. TD Cowen upped their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday, March 30th. Finally, Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Ten equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently made changes to their positions in the business. Torren Management LLC acquired a new stake in shares of United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC increased its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the fourth quarter valued at $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.